Member Info for draft

international player. I think Ineos

if this does a Serica

look at the Serica chart. look what happened

I'm aiming for double digits

could open at 4p happy days. major oil and gas player in exclusive talks. this may well be the next Serica!

on a block so this will.go revenue positive at some point.

if algy does a big deal fireworks

https://ore.catapult.org.uk/stories/remote-supervisory-systems/

cuz im hoping Spencer just pays for the whole drill cuz he can and ipgl has gone large here over 10%

2 of our blocks are with PARKMEAD as operator - 41% COS on Blackadder project

at some point this will generate revenue in my opinion

IPGL owner spencer - IPGL owns 10% of CLNR

Michael Spencer is set for a £90 million boost to his proceeds from selling the NEX broking firm, thanks to the strengthening US dollar and a rise in the share price of the buyer.

NEX and CME, the giant American exchanges group, came a step closer to cementing the deal after it was cleared yesterday by the Competition and Markets Authority.

Provided that the sale, which has been structured as a scheme of arrangement, is sanctioned in a final court hearing today, trading in NEX shares will be suspended and it will be completed tomorrow.

The energy giant Shell is to increase the amount of gas processed at a Norfolk terminal by 16% - securing its future for "decades to come".

The firm has spent £300m updating the plant at Bacton to allow 400 million cubic feet (11,300 litres) of gas to be processed.

"This means we can use the facilities more and reduce operating costs," Anne O'Halloran, from Shell, said.

This firm is also drilling more wells in the Southern North Sea gas field.

The extra capacity at the plant enables Shell to take gas from the Spirit Energy-owned Clipper South field, which is about 45 miles (70km) off the coast from Bacton.

Processing at Bacton, on the coast near North Walsham, began in 1968 after Shell discovered one of the largest gas fields in the Southern North Sea.

About a third of Britain's gas energy needs are supplied from the plant.

Manager Belinda Ikazoboh said Shell had invested the money to upgrade and extend the life of the plant so that it could supply Britain's energy needs "for decades to come".

https://www.bbc.co.uk/news/uk-england-norfolk-46307085

main focus of the company is investing in AI. "AI is exploding in all industries, not just the medical field, and exposing exciting new opportunities every day," said Schmainda. "This is just one application we felt we could leverage. It's very promising that other scientists and groups are attempting to do similar things with AI, as it demonstrates that substantial leaps in technology are not that far away."  Imaging Biometrics is owned by IQ-AI, an enterprise based on the Island of Jersey off the U.K. coastline.  The system is currently in development and undergoing testing in clinical trials.

the time, Norris and his wife, Gena, had filed a lawsuit against 11 companies, accusing them of producing GBCA products that posed harm to patients. They claim that the use of these substances led Gena to develop Gadolinium Deposition Disease following a number of MR scans and led to out-of-pocket hospitalization costs for her treatment that amounted to $2 million or more.  Because of such claims, many scientists and organizations are exploring the development of not just contrast-free exams but alternative agents, or solutions that cut down on the amount of gadolinium exposure that patients are subjected to. Nanoscientists at Rice University and the University of Texas MD Anderson Cancer Center, for instance, recently developed an alternative agent, embedded with iron chelates, to outperform gadolinium and spare patients from alleged health risks.  This, however, is not the only area being explored in AI, with Imaging Biometrics itself developing other software that deploys sophisticated algorithms to assess the MR and CT scans that help clinicians make diagnoses. A possible scenario could be the evaluation of blood supply in an area of the body to help determine if a mass is a tumor or scar tissue. 

The MR technologists and nurses not having to administer a dose of contrast to patients will speed up clinical workflows," Michael Schmainda, president of Imaging Biometrics, told HCB News. "There are even times when the contrast agent isn't administered properly resulting in poor scan quality. This may cause the exam to be rescheduled, inconveniencing the patient and their care provider as well as wasting scanner time. Those wasted costs, including the expense of gadolinium itself, could be avoided in the future."  The software consists of a deep-learning neural network trained with a large number of data sets that condition it to project or simulate where the contrast agent would normally appear. Data sets include DWI, T1 or Flair. The idea of non-contrast imaging is a popular idea among many organizations and individuals, with much of the drive behind it fueled by debates over the alleged negative side effects associated with gadolinium exposure.  “These companies continue to say that there is no link between gadolinium and adverse events, even though the evidence is overwhelming that this heavy metal stays in the body for years, rather than hours,” said actor and action star Chuck Norris in a statement last year. 

https://m.dotmed.com/news/story/45081

why are you not on t w a t t er. im not posting here again...

interesting if a rto happened. very low mcap here.

from Synairgen.

it was okay. they were all very friendly.